20 Geographic Atrophy Clinical Trials in New Haven, CT (2026)

Q: How do I join a clinical trial in New Haven?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you.

Recruiting Geographic Atrophy Studies in New Haven

NCT04373564Recruiting

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the orga...

New Haven, CT2,076 participantsGuerbet

View Study Details

NCT06841354Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sac...

New Haven, CT1,000 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06731478Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus stan...

New Haven, CT726 participantsDaiichi Sankyo

View Study Details

NCT06103864Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemot...

New Haven, CT625 participantsAstraZeneca

View Study Details

NCT06901531Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with che...

New Haven, CT500 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07218926Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) w...

New Haven, CT450 participantsGlaxoSmithKline

View Study Details

NCT03827694Recruiting

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI)....

New Haven, CT400 participantsArkansas Children's Hospital Research Institute

View Study Details

NCT07040566Recruiting

A Trial of Varenicline for E-cigarette Cessation

This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes....

New Haven, CT326 participantsYale University

View Study Details

NCT04787042Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

New Haven, CT316 participantsSimcha IL-18, Inc.

View Study Details

NCT06188585Recruiting

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in p...

New Haven, CT278 participantsMedtronic - MITG

View Study Details

NCT07021066Recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors....

New Haven, CT160 participantsSystImmune Inc.

View Study Details

NCT07066189Recruiting

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

The purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative breast cancer (TNBC) receiving chemo-immun...

New Haven, CT160 participantsYale University

View Study Details

NCT06655246Recruiting

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) ...

New Haven, CT157 participantsKura Oncology, Inc.

View Study Details

NCT07001748Recruiting

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdomi...

New Haven, CT148 participantsECOG-ACRIN Cancer Research Group

View Study Details

NCT06953882Recruiting

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

This is a Phase II, two-arm, single center, patient preference study designed to evaluate the impact of omitting adjuvant chemotherapy in moderate to high-anatomical risk, low-genomic risk (men or pre...

New Haven, CT140 participantsYale University

View Study Details

NCT06963931Recruiting

Change 4 Better (C4B)

The purpose of this research study is to determine the effectiveness of the Change4Better (C4B) mobile app at reducing the severity of problem gambling as compared to standard treatment as usual (TAU)...

New Haven, CT128 participantsYale University

View Study Details

NCT07215780Recruiting

SORE Study: Sitz Baths After Urogynecologic Reconstruction

The purpose of this study is to evaluate the utility of postoperative sitz baths in patient pain perception and recovery following surgical repair of prolapse. The SORE Study is a prospective, randomi...

New Haven, CT112 participantsYale University

View Study Details

NCT06963905Recruiting

Saci Nivo Rela for TNBC

This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlima...

New Haven, CT60 participantsYale University

View Study Details

NCT06712407Recruiting

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have comple...

New Haven, CT60 participantsCalliditas Therapeutics AB

View Study Details

NCT04422912Recruiting

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-...

New Haven, CT40 participantsCabaletta Bio

View Study Details

About Geographic Atrophy Clinical Trials in New Haven

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 20 geographic atrophy clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 7,862 participants. Research is being sponsored by Guerbet, Merck Sharp & Dohme LLC, Daiichi Sankyo and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in New Haven — FAQ

Are there geographic atrophy clinical trials in New Haven?

Yes, there are 20 geographic atrophy clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 20 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated July 13, 2026 from ClinicalTrials.gov